Roche gets $12 billion stock boost from positive cancer, hemophilia results

ZURICH (Reuters) - Roche shares were lifted on Monday by two trial wins for its new cancer and hemophilia drugs, potential blockbusters that the Swiss drugmaker is counting on to offset shrinking revenue from older medicines.